MCM
CDAK

Moore Capital Management’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Moore Capital Management’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,942
Closed -$676K – 827
2020
Q4 		$676K Buy
+20,942
New +$277K 0.01% 442

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Moore Capital Management's CDAK Position: Q1 2021 in Review

Moore Capital Management sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2021, closing a stake of 20,942 shares — an estimated $676K sold.

Moore Capital Management first reported a position in CDAK in Q4 2020 and held it in 1 quarter. The position peaked at $676K in Q4 2020. 47 funds tracked by Wall St. Rank hold CDAK as of Q1 2021.

  • Moore Capital Management reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Moore Capital Management sold 20,942 Codiak BioSciences, Inc. Common Stock shares in Q1 2021, an estimated $676K.
  • Moore Capital Management first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Moore Capital Management's Codiak BioSciences, Inc. Common Stock position peaked at $676K in Q4 2020.
  • 47 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2021.

Based on Moore Capital Management's 13F filing for Q1 2021, filed 17 May 2021.